NO943723L - Anvendelse av kinolin-3-karboksamidforbindelser for behandling av diabetes - Google Patents
Anvendelse av kinolin-3-karboksamidforbindelser for behandling av diabetesInfo
- Publication number
- NO943723L NO943723L NO943723A NO943723A NO943723L NO 943723 L NO943723 L NO 943723L NO 943723 A NO943723 A NO 943723A NO 943723 A NO943723 A NO 943723A NO 943723 L NO943723 L NO 943723L
- Authority
- NO
- Norway
- Prior art keywords
- diabetes
- quinoline
- hydrogen atoms
- treatment
- compound
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- BLTDCIWCFCUQCB-UHFFFAOYSA-N quinoline-3-carboxamide Chemical class C1=CC=CC2=CC(C(=O)N)=CN=C21 BLTDCIWCFCUQCB-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- UPZIXWLZXJSAEW-UHFFFAOYSA-N 4-hydroxy-n,1-dimethyl-2-oxoquinoline-3-carboxamide Chemical compound C1=CC=C2N(C)C(=O)C(C(=O)NC)=C(O)C2=C1 UPZIXWLZXJSAEW-UHFFFAOYSA-N 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- -1 quinoline-3-carboxamide compound Chemical class 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9201076A SE9201076L (sv) | 1992-04-06 | 1992-04-06 | Användningen av gamla läkemedel för behandling av diabetes |
| PCT/SE1993/000272 WO1993019756A1 (en) | 1992-04-06 | 1993-03-31 | The use of quinoline-3-carboxamide compounds for treatment of diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO943723D0 NO943723D0 (no) | 1994-10-05 |
| NO943723L true NO943723L (no) | 1994-10-05 |
Family
ID=20385863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO943723A NO943723L (no) | 1992-04-06 | 1994-10-05 | Anvendelse av kinolin-3-karboksamidforbindelser for behandling av diabetes |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5594005A (et) |
| EP (1) | EP0634931A1 (et) |
| JP (1) | JPH07506568A (et) |
| KR (1) | KR950700738A (et) |
| CN (1) | CN1081671A (et) |
| AU (1) | AU667362B2 (et) |
| CA (1) | CA2131831C (et) |
| EE (1) | EE03090B1 (et) |
| HU (1) | HUT69710A (et) |
| IL (1) | IL105285A0 (et) |
| NO (1) | NO943723L (et) |
| NZ (1) | NZ251494A (et) |
| PH (1) | PH30820A (et) |
| SE (1) | SE9201076L (et) |
| WO (1) | WO1993019756A1 (et) |
| ZA (1) | ZA932450B (et) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6133285A (en) * | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
| SE9802550D0 (sv) * | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE9802549D0 (sv) * | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| FR2827600A1 (fr) * | 2001-07-20 | 2003-01-24 | Lipha | Derives acides de quinolone et leurs applications en therapeutique |
| US8124582B2 (en) * | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| JP5619752B2 (ja) * | 2008-10-09 | 2014-11-05 | ニュートゥリー カンパニーリミテッド | パンドラチン誘導体またはボエセンベルギアパンドラタ抽出物の新規な用途 |
| WO2012050500A1 (en) | 2010-10-14 | 2012-04-19 | Lars Pettersson | 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators. |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1034124A (en) * | 1973-05-11 | 1978-07-04 | Ciba-Geigy Ag | Process for the manufacture of new quinolines |
| FR2340735A1 (fr) * | 1976-02-11 | 1977-09-09 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
| IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| DE3134780A1 (de) * | 1981-09-02 | 1983-03-10 | Hoechst Ag, 6000 Frankfurt | "sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung" |
| US5310913A (en) * | 1989-06-09 | 1994-05-10 | Kabi Pharmacia Aktiebolag | Derivatives of quinoline-3-carboxanilide |
| SE9000624D0 (sv) * | 1990-02-22 | 1990-02-22 | Pharmacia Ab | New use |
| SE9001111D0 (sv) * | 1990-03-27 | 1990-03-27 | Pharmacia Ab | Supportive use |
-
1992
- 1992-04-06 SE SE9201076A patent/SE9201076L/xx not_active Application Discontinuation
-
1993
- 1993-03-31 US US08/313,302 patent/US5594005A/en not_active Expired - Fee Related
- 1993-03-31 WO PCT/SE1993/000272 patent/WO1993019756A1/en not_active Ceased
- 1993-03-31 EP EP93908245A patent/EP0634931A1/en not_active Withdrawn
- 1993-03-31 NZ NZ251494A patent/NZ251494A/en unknown
- 1993-03-31 AU AU39131/93A patent/AU667362B2/en not_active Ceased
- 1993-03-31 HU HU9402854A patent/HUT69710A/hu unknown
- 1993-03-31 CA CA002131831A patent/CA2131831C/en not_active Expired - Fee Related
- 1993-03-31 JP JP5517372A patent/JPH07506568A/ja active Pending
- 1993-04-02 IL IL105285A patent/IL105285A0/xx unknown
- 1993-04-02 PH PH45991A patent/PH30820A/en unknown
- 1993-04-05 CN CN93105195A patent/CN1081671A/zh active Pending
- 1993-04-05 ZA ZA932450A patent/ZA932450B/xx unknown
-
1994
- 1994-10-05 NO NO943723A patent/NO943723L/no unknown
- 1994-10-06 KR KR1019940703534A patent/KR950700738A/ko not_active Ceased
- 1994-11-17 EE EE9400269A patent/EE03090B1/et unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA932450B (en) | 1993-10-20 |
| SE9201076L (sv) | 1993-10-07 |
| AU3913193A (en) | 1993-11-08 |
| IL105285A0 (en) | 1993-08-18 |
| CA2131831C (en) | 1999-03-09 |
| WO1993019756A1 (en) | 1993-10-14 |
| EE03090B1 (et) | 1998-06-15 |
| CA2131831A1 (en) | 1993-10-14 |
| NO943723D0 (no) | 1994-10-05 |
| AU667362B2 (en) | 1996-03-21 |
| HUT69710A (en) | 1995-09-28 |
| EP0634931A1 (en) | 1995-01-25 |
| PH30820A (en) | 1997-10-17 |
| KR950700738A (ko) | 1995-02-20 |
| HU9402854D0 (en) | 1995-01-30 |
| JPH07506568A (ja) | 1995-07-20 |
| SE9201076D0 (sv) | 1992-04-06 |
| NZ251494A (en) | 1997-07-27 |
| CN1081671A (zh) | 1994-02-09 |
| US5594005A (en) | 1997-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2000001786A0 (en) | Therapeutic uses of quinoline derivatives. | |
| BR0214164A (pt) | Ligantes do receptor canabinóide | |
| CA2036304A1 (en) | Pyrimidinedione derivatives, their production and use | |
| NZ333302A (en) | Substituted 6,5-hetero-bicyclic derivatives for the prevention or inhibition of a disorder that can be treated by antagonising corticotropin releasing factor | |
| HUP9801219A2 (hu) | Triciklusos N-acilezett benzazepin és benzoxazepinszármazékok, az ezeket tartalmazó gyógyszerkészítmények, eljárás előállításukra | |
| YU1501A (sh) | Derivati hinolina | |
| PL335518A1 (en) | 1,8-cycled n- or c-bound imidazole substituted derivatives of quinolynone inhibiting farnesil transferase | |
| IL157179A0 (en) | Fused heterocyclic compounds | |
| CA2112331A1 (en) | Novel naphthalene derivatives | |
| MY113733A (en) | Salts of an anti-migraine indole derivative | |
| NO924929L (no) | Farmasoeytisk aktive benzoquinazolinforbindelser | |
| NO941273L (no) | Ny anvendelse av substituert kinolinkarboksamid | |
| NO954072D0 (no) | Vannopplöselige camptotecinderivater, fremgangsmåte for deres fremstilling og deres anvendelse som antitumormidler | |
| NO943723L (no) | Anvendelse av kinolin-3-karboksamidforbindelser for behandling av diabetes | |
| SE9302490D0 (sv) | New use of old drugs | |
| ES2126890T3 (es) | Preparacion de complejos de monociclopentadienilo con metales mediante sustitucion nucleofila de complejos de bis(ciclopentadienilo) con metales. | |
| SE9400810D0 (sv) | New use of Quinoline-3-carboxamide compounds | |
| DK0613687T3 (da) | Anvendelse af pregnanderivat til behandling af tumorer | |
| SE9400809D0 (sv) | New use of quinoline-3-carboxamide compounds | |
| TW344742B (en) | Indole derivatives and the medical used thereof | |
| EP0543018A4 (en) | Antidiabetic | |
| CA2163122A1 (en) | Positive inotropic and lusitropic pyrroloquinolinone derivatives | |
| GB1252847A (et) | ||
| GB1337371A (en) | 3-amino-imidazo-1,5-a- pyridines processes for their preparation and pharmaceutical compositions incorporating them | |
| AU1855088A (en) | Treating agent for heart failure |